Vertex snags another FDA 'breakthrough' status
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has snagged another breakthrough therapy designation from the FDA, this time for VX-661 in combination with ivacaftor to treat patients with cystic fibrosis (CF) who have two copies of the F508del mutation.